Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: A critical reassessment

AIDS Research and Human Retroviruses

Volumn 15, Issue 16, 1999, Pages 1405-1412

  Powderly, William G ^a   Mayer, Kenneth H ^b   Perfect, John R ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; CLOTRIMAZOLE; CORTICOSTEROID; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; PSYCHOTROPIC AGENT; PYRROLE DERIVATIVE; WARFARIN;

ANTIBIOTIC RESISTANCE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENCY; FUNGUS CULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MOUTH LESION; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; STAINING; THRUSH; TOPICAL DRUG ADMINISTRATION;

EID: 0033230445     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299309900     Document Type: Review

References (53)

1. Dismukes WE: Candidiasis. In: Cecil Textbook of Medicine (Bennett JC and Plum F, eds.), 20th Ed. W.B. Saunders, Philadelphia, 1996; pp. 1827-1830.
2. Samaranayake LP: Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol 1992;73:171-180.
3. American Thoracic Society: Fungal infection in HIV-infected persons. Am J Respir Crit Care Med 1995;152:816-822.
4. Reef SE and Mayer KH: Opportunistic candidal infections in patients infected with human immunodeficiency virus: Prevention issues and priorities. Clin Infect Dis 1995;21(Supp. 1):S99-S102.
5. Powderly WG: Resistant candidiasis. AIDS Res Hum Retroviruses 1994;10:925-929.
6. Darouiche RO: Oropharyngeal and esophageal candidiasis in immunocompromised patients: Treatment issues. Clin Infect Dis 1998;26:259-274.
7. Fichtenbaum CF and Powderly WG: Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998;26:556-565.
8. Chaisson RE and Volberding PA: Clinical manifestations of HIV infection. In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases (Mandell GL, Bennett JE, and Dolin R, eds.), 4th Ed. Churchill Livingstone, New York, 1995, pp. 1217-1253.
9. Moore RD and Chaisson RE: Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996;124:633-642.
10. Glick M, Muzyka BC, Lurie D, and Salkin LM: Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 1994; 77:344-349.
11. Kinlock-DeLose S, Hirschel B, Hoen B, et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-413.
12. Hood S, Bonington A, Evans J, and Denning D: Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998;12:447-448.
13. Valdez H, Gripshover BM, Salata RA, and Lederman MM: Resolution of azole-resistance oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. AIDS 1998;12:538.
14. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
15. Costagliola D: Trends in incidence of clinical manifestations of HIV infection and antiretroviral prescriptions in French university hospitals. In: Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998; Chicago, Illinois. Abstract 182.
16. Martins MD, Lozano-Chiu M, and Rex JH: Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;27:1291-1294.
17. Little JW, Melnick SL, Rhame FS, Balfour HH, et al.: Prevalence of oral lesions in symptomatic and asymptomatic HIV patients. Gen Dent. 1994;42:446-450.
18. Samaranayake LP and Holmstrup P: Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989;18: 554-564.
19. Greenspan D and Greenspan JS: The oral clinical features of HIV infection. Gastroenterol Clin North Am 1988;17:535-543.
20. Pons V, Greenspan D, Lozada-Nur F, McPhail L, et al.: Oropharyngeal candidiasis in patients with AIDS: Randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997;24:1204-1207.
21. Flynn PM, Cunningham CK, Kerkering T, San Jorge AR, et al.: Oropharyngeal candidiasis in immunocompromised children: A randomized, multicenter study of orally administered fluconazole suspension versus nystatin. J Pediatr 1995;127:322-328.
22. Gombert ME, duBouchet L, Aulicino TM, and Butt KMH: A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants: Use in prophylaxis of oropharyngeal candidiasis. JAMA 1987;258:2553-2555.
23. Kirkpatrick CH and Ailing DW: Treatment of chronic oral candidiasis with clotrimazole troches: A controlled clinical trial. N Engl J Med 1978;299:1201-1203.
24. Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, et al.: Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 1984;144:290-293.
25. Yeo E, Alvarado T, Fainstein V, and Bodey GP: Prophylaxis of oropharyngeal candidiasis with clotrimazole. J Clin Oncol 1985;3: 1668-1671.
26. Montes LF, Soto TG, Parker JM, and Ramer GN: Clotrimazole troches: A new therapeutic approach to oral candidiasis. Cutis 1975;17:277-280.
27. Yap B-S and Bodey GP: Oropharyngeal candidiasis treated with a troche form of clotrimazole. Arch Intern Med 1979;193:656-657.
28. Koletar SL, Russell JA, Fass RJ, and Plouffe JF: Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990;34:2267-2268.
29. Dewsnup DH and Stevens DA: Efficacy of oral amphotericin B in AIDS patients with thrust clinically resistant to fluconazole. J Med Vet Mycol 1994;32:389-393.
30. Nguyen MT, Weiss PJ, Labarre RC, and Wallace MR: Oral amphotericin B (AmB) in the treatment of oral candidiasis (OC) due to azole-resistant Candida species. In: Program and Abstracts of the 32nd Annual Meeting of the Infectious Diseases Society of America, 1994, Orlando, Florida. Abstract 287.
31. Zingman B, Zackin R, Wheat J, Rajicic N, et al.: Amphotericin B oral suspension for fluconazole-resistant oral candidiasis in HIV-infected patients. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997, Toronto, Ontario, Canada. Abstract I-152.
32. Piscitelli SC, Flexner C, Minor JR, et al.: Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-693.
33. Cartledge JD, Midgely J, and Gazzard BG: Itraconazole solution: Higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 1997;50:477-480.
34. Phillips P, De Beule K, Frechette G, et al.: A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998;26:1368-1373.
35. Pons V, Greenspan D, Debruin M, and the Multicenter Study Group: Therapy for oropharyngeal candidiasis in HIV-infected patients: A randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J Acquir Immune Defic Syndr 1993;6:1311-1316.
36. Sangeorzan JA, Bradley SF, He X, Zarins, LT, et al.: Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-346.
37. Murray PA, Koletar SL, Mallegoll, Wu J, et al.: Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Therapeut 1997;19:417-480.
38. Darouiche RO, Graybill JR, Vazquez J, Murray P, Wu J, and Moskovitz BL: Itraconazole oral solution (IS) for the treatment of oropharyngeal candidiasis (OC): Results of two randomized, blinded studies. In: Program and Abstracts of the XIth International Conference on AIDS, July 7-12, 1996; Vancouver, British Columbia, Canada. Abstract Mo.B.117.
39. DeWitt S, Weerts D, Goossens H, and Clumeck N: Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;1:746-748.
40. Graybill JR, Vazquez J, Darouiche RO, et al.: Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998;104:33-39.
41. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, et al.: Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997;24:235-247.
42. Baily GC, Perry FM, Denning DW, and Mandal BK: Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994;8:787-792.
43. Millon L, Manteaux A, Reboux G, Drobacheff C, et al.: Fluconazole-resislant recurrent oral candidiasis in human immunodeficiency virus-positive patients: Persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994;32:1115-1118.
44. Vuffray A, Durussel C, Boerlin P, Boerlin-Petzold F, et al.: Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994;8:708-709.
45. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, et al.: Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996;174:821-827.
46. Troillet N, Durussel C, Bille J, Glauser MP, et al.: Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993;12:911-915.
47. Maenza JR, Keruly JC, Moore RD, Chaisson RE, et al.: Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996;173:219-225.
48. Akova M, Akalin HE, Uzun O, and Gür D: Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 1991;10:598-599.
49. Coleman DC, Rinaldi MG, Haynes KA, et al.: Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol 1998;36(Suppl. 1):156-165.
50. Fichtenbaum CJ, Koletar S, Yiannoutsos C, Chen D, et al.: Fluconazole resistant mucosal candidiasis in advanced HIV infection. In: Program and Abstracts of the XIth International Conference on AIDS, July 7-12, 1996, Vancouver, British Columbia, Canada. Abstract Mo.B.112.
51. USPHS/IDSA Prevention of Opportunistic Infections Working Group: USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations. Clin Infect Dis 1995;21 (Suppl. 1):S32-S43.
52. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary. Ann Intern Med 1996;124:349-368.
53. Powderly WG, Landay A, and Lederman M: Recovery of the immune system with antiretroviral therapy: The end of opportunism? JAMA 1998;280:72-77.